Chemoprevention of colorectal cancer with ursodeoxycholic acid: Cons

Elizabeth J. Carey, Keith Lindor

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Animal and human data suggest a relationship between bile acids, especially secondary bile acids, and colorectal cancer. Ursodeoxycholic acid, a synthetic bile acid, has been shown in animal and . in vitro studies to reduce the risk of colonic dysplasia and cancer development. Human trials have focused on patients with history of adenoma, inflammatory bowel disease, primary sclerosing cholangitis, and primary biliary cirrhosis. Some studies suggest that ursodeoxycholic may reduce the colorectal cancer risk, but to date the studies are small, mostly retrospective, and lacking in solid evidence to support use of UDCA for colorectal cancer chemoprophylaxis.

Original languageEnglish (US)
Pages (from-to)S61-S64
JournalClinics and Research in Hepatology and Gastroenterology
Volume36
Issue numberSUPPL.1
DOIs
StatePublished - Sep 1 2012

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Chemoprevention of colorectal cancer with ursodeoxycholic acid: Cons'. Together they form a unique fingerprint.

  • Cite this